Congress:
ECR24
Poster Number:
C-11689
Type:
EPOS Radiographer (scientific)
Authorblock:
J. S. Endrikat1, A. Ullmann1, C. Gerlinger1, A. Bhatti2, P. Lengsfeld1, A. Michel3; 1Berlin/DE, 2Whippany, NJ/US, 3Basel/CH
Disclosures:
Jan Siegfried Endrikat:
Author: Bayer AG Employee: Bayer AG
Alexander Ullmann:
Author: Bayer AG Employee: Bayer Ag
Christoph Gerlinger:
Author: Bayer AG Employee: Bayer Ag
Aasia Bhatti:
Author: Bayer AG Employee: Bayer Ag
Philipp Lengsfeld:
Employee: Bayer Ag Author: Bayer AG
Alexander Michel:
Employee: Bayer Ag Author: Bayer AG
Keywords:
Contrast agents, CT, Contrast agent-intravenous, Safety, Drugs / Reactions
Two analyses were performed.
1.) The “Phase-IV-Analysis” evaluated an integrated pooled database of 4 non-interventional studies (1-4). It was a nested case-control analysis of patients who received an injection of iopromide 300 or 370mg iodine/mL. Cases were patients with a typical/unequivocal HSR.
2.) The “GPV-Analysis” evaluated all case reports from the company’s global pharmacovigilance database. It was based on HSR case reports in the company database. Exposure estimates were derived from sales and market research data.